Inhibitors of purine and pyrimidine synthesis: Mycophenolate, azathioprine, and leflunomide

Dermatologic Therapy

Volumn 15, Issue 4, 2002, Pages 311-316

  Mimouni, Daniel ^a   Nousari, H Carlos ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Azathioprine; Leflunomide; Mycophenolate mofetil

Indexed keywords

ALUMINUM HYDROXIDE; ANTACID AGENT; AZATHIOPRINE; CAPTOPRIL; COLESTYRAMINE; CYCLOSPORIN; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; INTERLEUKIN 10 RECEPTOR; LEFLUNOMIDE; LIVE VACCINE; LIVER ENZYME; MAGNESIUM; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PURINE ANTAGONIST; PURINE SYNTHESIS INHIBITOR; PYRIMIDINE ANTAGONIST; PYRIMIDINE SYNTHESIS INHIBITOR; RIFAMPICIN; UNCLASSIFIED DRUG; WARFARIN;

ABDOMINAL CRAMP; ALOPECIA; ANEMIA; AUTOIMMUNE DISEASE; BLISTER; CELL DEATH; CELL DIVISION; CLINICAL FEATURE; DIARRHEA; DISCOID LUPUS ERYTHEMATOSUS; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG EXCRETION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; ECZEMA; FATIGUE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HYPERSENSITIVITY; IMMUNOMODULATION; INHIBITION KINETICS; INSOMNIA; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER TOXICITY; MUSCLE WEAKNESS; NEUROLOGIC DISEASE; NEUTROPENIA; PANCREATITIS; PANCYTOPENIA; PEMPHIGUS; PRACTICE GUIDELINE; PSORIASIS VULGARIS; PURINE SYNTHESIS; PYODERMA GANGRENOSUM; PYRIMIDINE SYNTHESIS; PYURIA; QUALITY OF LIFE; REVIEW; THROMBOCYTOPENIA; TINNITUS; TOXIC HEPATITIS; TREATMENT INDICATION; URINARY FREQUENCY; URINARY URGENCY; UROGENITAL TRACT DISEASE; VOMITING;

EID: 0036968452     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1529-8019.2002.01539.x     Document Type: Review

References (40)

1. Stanley JR. Pemphigus. In: Freedberg IM, Eisen AZ, Wolff K, et al., eds. Fitzpatrick's dermatology in general medicine, 5th ed. New York: McGraw-Hill, 1999: 654-666.
2. Chan GL, Canafax DM, Johnson CA. The therapeutic use of azathioprine in renal transplantation. Pharmacotherapy 1987: 7: 165-177.
3. Badalamenti S, Kerdel FA. Azathioprine. In: Wolverton SE, ed. Comprehensive dermatologic drug therapy, 1st ed. Philadelphia: WB Saunders, 2001: 165-179.
4. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992: 43: 329-339.
5. Tai HL, Krynetski EY, Yates CR, et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996: 58: 694-702.
6. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997: 126: 608-614.
7. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 1995: 131: 193-197.
8. Aberer W, Wolff-Schreiner EC, Stingl G, Wolff K. Azathioprine in the treatment of pemphigus vulgaris. A long-term follow-up. J Am Acad Dermatol 1987: 16: 527-533.
9. Primka EJ III, Camisa C. Psoriasis and bullous pemphigoid treated with azathioprine. J Am Acad Dermatol 1998: 39: 121-123.
10. Tan BB, Lear JT, Gawkrodger DJ, English JS. Azathioprine in dermatology: a survey of current practice in the UK. Br J Dermatol 1997: 136: 351-355.
11. Abu-Shakra M, Shoenfeld Y. Azathioprine therapy for patients with systemic lupus erythematosus. Lupus 2001: 10: 152-153.
12. Baughman RP, Lower EE. Alternatives to corticosteroids in the treatment of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1997: 14: 121-130.
13. Callen JP, Spencer LV, Burruss JB, Holtman J. Azathioprine. An effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol 1991: 127: 515-522.
14. Kaklamani VG, Kaklamanis PG. Treatment of Behcet's disease - an update. Semin Arthritis Rheum 2001: 30: 299-312.
15. Norris PG, Hawk JL. Successful treatment of severe polymorphous light eruption with azathioprine. Arch Dermatol 1989: 125: 1377-1379.
16. Shupack JL, Silverman Kitchin JE, Stiller MJ, Webster GF. Cytotoxic and antimetabolic agents. In: Freedberg IM, Eisen AZ, Wolff K, et al., eds. Fitzpatrick's dermatology in general medicine, 5th ed. New York: McGraw-Hill, 1999: 2797-2810.
17. Tavadia SM, Mydlarski PR, Reis MD, et al. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J Am Acad Dermatol 2000: 42: 628-632.
18. Gross R. Hepatotoxicity of 6-mercaptopurine and azathioprine. Mayo Clin Proc 1994: 69: 498.
19. Kawanishi H, Rudolph E, Bull FE. Azathioprine-induced acute pancreatitis. N Engl J Med 1973: 289: 357.
20. Pozniak AL, Ahern M, Blake DR. Azathioprine-induced shock. Br Med J (Clin Res Ed) 1981: 283: 1548.
21. Pozniak AL. Azathioprine-induced pancreatitis. Arthritis Rheum 1982: 25: 1149.
22. Smak Gregoor PJ, van Saase JL, Weimar W, Kramer P. Fever and rigors as sole symptoms of azathioprine hypersensitivity. Neth J Med 1995: 47: 288-290.
23. Nousari HC, Griffin WA, Anhalt GJ. Successful therapy for bullous pemphigoid with mycophenolate mofetil. J Am Acad Dermatol 1998: 39: 497-498.
24. Kitchin JE, Pomeranz MK, Pak G, Washenik K, Shupack JL. Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. J Am Acad Dermatol 1997: 37: 445-449.
25. Bullingham R, Monroe S, Nicholls A, Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996: 36: 315-324.
26. Nousari HC, Anhalt GJ. The role of mycophenolate mofetil in the management of pemphigus. Arch Dermatol 1999: 135: 853-854.
27. Nousari HC, Anhalt GJ. Immunosuppressive and immunomodulatory drugs. In: Freedberg IM, Eisen AZ, Wolff K, et al., eds. Fitzpatrick's dermatology in general medicine, 5th ed. New York: McGraw-Hill, 1999: 2853-2868.
28. Allison AC, Kowalski WJ, Muller CJ, Waters RV, Eugui EM. Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant Proc 1993: 25: 67-70.
29. Enk AH, Knop J. Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol 1999: 135: 54-56.
30. Grundmann-Kollmann M, Kaskel P, Leiter U, et al. Treatment of pemphigus vulgaris and bullous pemphigoid with mycophenolate mofetil monotherapy. Arch Dermatol 1999: 135: 724-725.
31. Grundmann-Kollmann M, Korting HC, Behrens S, et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol 1999: 40: 957-960.
32. Nousari HC, Sragovich A, Kimyai-Asadi A, Orlinsky D, Anhalt GJ. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol 1999: 40: 265-268.
33. Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000: 59: 841-849.
34. Laan RF, van Riel PL, van de Putte LB. Leflunomide and methotrexate. Curr Opin Rheumatol 2001: 13: 159-163.
35. Siemasko K, Chong AS, Jack HM, Gong H, Williams JW, Finnegan A. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol 1998: 160: 1581-1588.
36. Alldred A, Emery P. Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis. Expert Opin Pharmacother 2001: 2: 125-137.
37. Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol 1999: 162: 2095-2102.
38. Mirmohammadsadegh A, Homey B, Abts HF, Kohrer K, Ruzicka T, Michel G. Differential modulation of pro-and anti-inflammatory cytokine receptors by N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxy-crotonic acid amide (A77 1726), the physiologically active metabolite of the novel immunomodulator leflunomide. Biochem Pharmacol 1998: 55: 1523-1529.
39. Nousari HC, Anhalt GJ. Bullous pemphigoid treated with leflunomide: a novel immunomodulatory agent. Arch Dermatol 2000: 136: 1204-1205.
40. Smolen JS, Emery P. Efficacy and safety of leflunomide in active rheumatoid arthritis. Rheumatology (Oxford) 2000: 39: 48-56.